The role of glimepiride in the treatment of type 2 diabetes mellitus

Bibliography

• Wild S, Roglic G, Green A, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53
   PubMed Web of Science ®Google Scholar
• Procopiou M, Philippe J. The metabolic syndrome and type 2 diabetes: epidemiological figures and country specificities. Cerebrovasc Dis 2005;20(Suppl 1):2-8
   PubMedGoogle Scholar
• World Health Organization. Fact sheet number 312: diabetes. Media centre fact sheet 2008. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/. [Cited 20 June 2009]
   Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86
   PubMed Web of Science ®Google Scholar
• Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications 2004;18(6):367-76
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation Clinical Guidelines Task Force. Global guidelines for type 2 diabetes. 2005. Available from: http://www.idf.org/Global_guideline. [Cited 20 June 2009]
   Google Scholar
• Beisswenger PJ, Dias N, Beckman F. Evaluation of first-generation sulfonylureas and glipizide in non-insulin-dependent diabetes mellitus. Am J Med 1987;83(3A):16-21
   PubMed Web of Science ®Google Scholar
• Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 2003;25(3):799-816
   PubMed Web of Science ®Google Scholar
• Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32(10):1044-52
   PubMed Web of Science ®Google Scholar
• Epocrates. Glimepiride. Drug Monographs 2009. Available from: https://online.epocrates.com/noFrame/showPage.do?method=drugs& MonographId=381&ActiveSectionId=10. [Cited 21 June 2009]
   Google Scholar
• Badian M, Korn A, Lehr KH, Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metabol Drug Interact 1994;11(4):331-9
   PubMedGoogle Scholar
• Matsuki M, Matsuda M, Kohara K, Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. Endocr J 2007;54(4):571-6
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17(6):467-73
   PubMed Web of Science ®Google Scholar
• Caulfield M, O'Brien K. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clin Diabetes 2002;20(2):81-4
   Google Scholar
• Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 2000;50(Suppl 1):S47
   PubMedGoogle Scholar
• Scholz G, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort study. Clin Drug Invest 2001;21(9):597-604
   Web of Science ®Google Scholar
• Sanofi-Aventis Canada, Inc. Product Monograph (Amaryl, glimepiride). 2009
   Google Scholar
• Overkamp D, Volk A, Maerker E, Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 2002;25(11):2065-73
   PubMed Web of Science ®Google Scholar
• Muller G, Wied S, Straub J, Jung C. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the anti-diabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur J Pharmacol 2008;597(1-3):6-18
   PubMed Web of Science ®Google Scholar
• Mazzone T, Meyer PM, Feinstein SB, Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296(21):2572-81
   PubMed Web of Science ®Google Scholar
• NCBI Pubchem Compound Database. National Center for Biotechnology Information. Glimepiride. 2009. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3476&loc=ec_rcs. [Cited 21 June 2009]
   Google Scholar
• Kramer W, Muller G, Girbig F, Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochim Biophys Acta 1994;1191(2):278-90
   PubMed Web of Science ®Google Scholar
• Muller G, Hartz D, Punter J, Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994;1191(2):267-77
   PubMed Web of Science ®Google Scholar
• Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother 2004;38(1):30-5
   PubMed Web of Science ®Google Scholar
• Rosenkranz B, Profozic V, Metelko Z, Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39(12):1617-24
   PubMed Web of Science ®Google Scholar
• Malerczyk V, Badian M, Korn A, Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. Drug Metabol Drug Interact 1994;11(4):341-57
   PubMedGoogle Scholar
• Niemi M, Cascorbi I, Timm R, Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002;72:326-32
   PubMed Web of Science ®Google Scholar
• Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res 1996;28(9):434-9
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Thomas A, Reid L, Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25(9):1607-11
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996;19(11):1194-9
   PubMed Web of Science ®Google Scholar
• Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol Med 2000;6(11):907-33
   PubMed Web of Science ®Google Scholar
• Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995;28(Suppl):S115-37
   PubMedGoogle Scholar
• Haupt A, Kausch C, Dahl D, Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide. Diabetes Care 2002;25(12):2129-32
   PubMed Web of Science ®Google Scholar
• Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol 2001;133(1):193-9
   PubMed Web of Science ®Google Scholar
• Mocanu MM, Maddock HL, Baxter GF, Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001;103(25):3111-6
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996;19(8):849-56
   PubMed Web of Science ®Google Scholar
• Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38(7):636-41
   PubMed Web of Science ®Google Scholar
• Sonnenberg GE, Garg DC, Weidler DJ, Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother 1997;31(6):671-6
   PubMed Web of Science ®Google Scholar
• Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996;28(9):426-9
   PubMed Web of Science ®Google Scholar
• Draeger KE, Wernicke-Panten K, Lomp HJ, Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996;28(9):419-25
   PubMed Web of Science ®Google Scholar
• Charpentier G, Fleury F, Kabir M, Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18(10):828-34
   PubMed Web of Science ®Google Scholar
• McCluskey D, Touger MS, Melis R, Schleusener DS. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin Ther 2004;26(11):1783-90
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006;22(4):751-9
   PubMed Web of Science ®Google Scholar
• Garber AJ. Benefits of combination therapy of insulin and oral hypoglycemic agents. Arch Intern Med 2003;163(15):1781-2
   PubMed Web of Science ®Google Scholar
• Riddle MC. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Horm Metab Res 1996;28(9):430-3
   PubMed Web of Science ®Google Scholar
• Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998;21(7):1052-7
   PubMed Web of Science ®Google Scholar
• Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Ann Pharmacother 2003;37(11):1572-6
   PubMed Web of Science ®Google Scholar
• Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138(12):952-9
   PubMed Web of Science ®Google Scholar
• Martin S, Kolb H, Beuth J, Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003;46(12):1611-7
   PubMed Web of Science ®Google Scholar
• Meinert C, Knatterud G, Prout T, Cr K. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl 2):789-830
   PubMedGoogle Scholar
• Food and Drug Administration. Amaryl (glimepiride tablets) Label. Available from: http://wwwaccessdatafdagov/drugsatfda_docs/label/2009/020496s021lblpdf: FDA 2009
   Google Scholar
• Kahn SE, Haffner SM, Heise MA, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
   PubMed Web of Science ®Google Scholar
• Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res 1996;28(9):451-5
   PubMed Web of Science ®Google Scholar